Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review.

Junya SatoMakoto KodairaHiroyuki HaradaHaruo IguchiTaichi YoshidaHiroyuki Shibatanull null

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

This meta-analysis showed no influence of BMA de-escalation on the incidence of SRE; nevertheless, AEs appeared to reduce with the de-escalated usage of ZA.

Keyphrases

systematic review
gestational age
meta analyses
risk factors
bone mineral density
open label
soft tissue
case control
clinical trial
randomized controlled trial
bone regeneration
postmenopausal women
study protocol